



(51) International Patent Classification:

A61K 35/38 (2015.01) A61P 25/00 (2006.01)
A61P 17/00 (2006.01) C12N 5/071 (2010.01)

(21) International Application Number:

PCT/US2024/014543

(22) International Filing Date:

06 February 2024 (06.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/483,399 06 February 2023 (06.02.2023) US

(71) Applicant: **BICARA THERAPEUTICS INC.** [US/US];
116 Huntington Avenue, Suite 703, Boston, Massachusetts
02116 (US).

(72) Inventors: **SALAZAR, Rachel**; c/o Bicara Therapeutics
Inc., 116 Huntington Avenue, Suite 703, Boston, Mass-
achusetts 02116 (US). **NAIR, Pradip**; c/o Bicara Thera-
peutics Inc., 116 Huntington Avenue, Suite 703, Boston,
Massachusetts 02116 (US). **BOREDDY, Srinivas Red-
dy**; c/o Bicara Therapeutics Inc., 116 Huntington Avenue,
Suite 703, Boston, Massachusetts 02116 (US). **PANDEY,
Prashant Kumar**; c/o Bicara Therapeutics Inc., 116 Hunt-

ington Avenue, Suite 703, Boston, Massachusetts 02116
(US). **KUMARA M. V, Prashantha**; c/o Bicara Therapeu-
tics Inc., 116 Huntington Avenue, Suite 703, Boston, Mass-
achusetts 02116 (US).

(74) Agent: **GRANT, Angela M.** et al.; Haynes and Boone,
LLP, 2801 N. Harwood St., Suite 2300, Dallas, Texas 75201
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: COMBINATION THERAPY AND RELATED METHODS




FIG. 7

(57) Abstract: Provided herein are methods comprising the use of KRAS (e.g., hKRAS) inhibitors in combination with an agent(s) that specifically binds to EGFR (e.g., hEGFR) and TGFβ (e.g., hTGFβ), as well as compositions and kits comprising the same. The methods provided herein are useful in methods of treating cancer, (e.g., KRAS (e.g., hKRAS) variant cancers). Further provided herein are combination regimens, combination compositions, pharmaceutical compositions, and kits comprising a KRAS (e.g., hKRAS) inhibitor and an agent(s) that specifically binds to EGFR (e.g., hEGFR) and TGFβ (e.g., hTGFβ).

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*